Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) saw a significant growth in short interest in June. As of June 15th, there was short interest totaling 10,679 shares, a growth of 597.5% from the May 31st total of 1,531 shares. Based on an average trading volume of 28,955 shares, the days-to-cover ratio is currently 0.4 days.
Defence Therapeutics Price Performance
Shares of DTCFF remained flat at $0.35 during mid-day trading on Friday. 6,150 shares of the stock were exchanged, compared to its average volume of 8,392. The firm has a 50-day moving average of $0.38 and a two-hundred day moving average of $0.44. Defence Therapeutics has a 12 month low of $0.31 and a 12 month high of $0.78.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Featured Articles
- Five stocks we like better than Defence Therapeutics
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
- Data Center Delays Create Opportunity in These 3 Stocks
- Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally Here
- Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
